GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Taihe Group Inc (OTCPK:TIHE) » Definitions » Notes Receivable

TIHE (Taihe Group) Notes Receivable : $0.00 Mil (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is Taihe Group Notes Receivable?

Taihe Group's Notes Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.


Taihe Group Notes Receivable Historical Data

The historical data trend for Taihe Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taihe Group Notes Receivable Chart

Taihe Group Annual Data
Trend Dec20 Dec21 Dec22
Notes Receivable
- - -

Taihe Group Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Taihe Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Taihe Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Taihe Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Taihe Group Business Description

Traded in Other Exchanges
N/A
Address
Indonesian Street City, Batu Licin, Bintan Island, Kepulauan Riau, IDN, 29151
Taihe Group Inc formerly, NuOncology Labs Inc is a United States based company and provides predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. NLAB's operations include development, identification, testing and licensing of cancer treatment compounds.

Taihe Group Headlines

No Headlines